{
    "clinical_study": {
        "@rank": "85898", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: Phase II trial to study the effectiveness of acridine carboxamide in treating\n      patients who have advanced non-small cell lung cancer that cannot be treated with surgery."
        }, 
        "brief_title": "Acridine Carboxamide in Treating Patients With Advanced Non-small Cell Lung Cancer", 
        "condition": "Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES: I. Determine the effect of acridine carboxamide on objective response, response\n      rate, and duration of response in patients with unresectable, locally advanced, progressive\n      or metastatic non-small cell lung cancer. II. Determine the toxicities and pharmacokinetics\n      of this regimen in these patients.\n\n      OUTLINE: This is a multicenter study. Patients receive acridine carboxamide IV over 24 hours\n      for 5 days. Treatment repeats every 3 weeks for a maximum of 6 courses in the absence of\n      disease progression or unacceptable toxicity. Patients are followed every 6 weeks until\n      disease progression or commencement of another treatment.\n\n      PROJECTED ACCRUAL: A total of 14-25 patients will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS: Histologically proven unresectable, locally advanced, progressive\n        or metastatic non-small cell lung cancer Not amenable to curative surgery or radiotherapy\n        No prior first line chemotherapy for metastatic or advanced disease At least 1\n        bidimensionally measurable target lesion by CT scan No symptomatic brain metastases\n\n        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At\n        least 3 months Hematopoietic: WBC greater than 3,000/mm3 Platelet count greater than\n        100,000/mm3 Hepatic: Bilirubin less than 1.5 times upper limit of normal (ULN) SGOT, SGPT,\n        and alkaline phosphatase no greater than 2 times ULN (5 times ULN if liver metastases\n        present) Renal: Creatinine no greater than 1.7 mg/dL Cardiovascular: No ischemic heart\n        disease within the past 6 months Normal 12 lead ECG Other: Not pregnant or nursing\n        Negative pregnancy test Fertile patients must use effective contraception No other prior\n        or concurrent malignancy except cone biopsied carcinoma of the cervix or adequately\n        treated basal or squamous cell skin cancer No unstable systemic disease or active\n        uncontrolled infection No psychological, familial, sociological, or geographical condition\n        that could preclude compliance\n\n        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease\n        Characteristics No prior chemotherapy Endocrine therapy: Not specified Radiotherapy: At\n        least 4 weeks since prior radiotherapy Surgery: At least 2 weeks since prior major surgery\n        Other: No other concurrent anticancer agents No other concurrent investigational therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 10, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004151", 
            "org_study_id": "EORTC-16991N", 
            "secondary_id": "EORTC-16991N"
        }, 
        "intervention": {
            "intervention_name": "acridine carboxamide", 
            "intervention_type": "Drug"
        }, 
        "keyword": [
            "recurrent non-small cell lung cancer", 
            "stage IIIA non-small cell lung cancer", 
            "stage IIIB non-small cell lung cancer", 
            "stage IV non-small cell lung cancer"
        ], 
        "lastchanged_date": "September 20, 2012", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/EORTC-16991N"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Vienna", 
                        "country": "Austria", 
                        "zip": "A-1100"
                    }, 
                    "name": "Kaiser Franz Josef Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Copenhagen", 
                        "country": "Denmark", 
                        "zip": "2100"
                    }, 
                    "name": "Rigshospitalet"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dijon", 
                        "country": "France", 
                        "zip": "21079"
                    }, 
                    "name": "Centre de Lute Contre le Cancer,Georges-Francois Leclerc"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marseille", 
                        "country": "France", 
                        "zip": "13385"
                    }, 
                    "name": "CHU de la Timone"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Munich", 
                        "country": "Germany", 
                        "zip": "D-80639"
                    }, 
                    "name": "Haemato-Onkologische Praxis und Tagesklinik"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Naples", 
                        "country": "Italy", 
                        "zip": "80131"
                    }, 
                    "name": "Istituto Nazionale per lo Studio e la Cura dei Tumori"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rome", 
                        "country": "Italy", 
                        "zip": "00161"
                    }, 
                    "name": "Istituti Fisioterapici Ospitalieri - Roma"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28041"
                    }, 
                    "name": "Hospital Universitario 12 de Octubre"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Austria", 
                "Denmark", 
                "France", 
                "Germany", 
                "Italy", 
                "Spain"
            ]
        }, 
        "official_title": "Open Label Phase II Study on XR5000 Administered as a 5 Day Infusion in Advanced Non Small Cell Lung Cancer", 
        "overall_official": {
            "affiliation": "Haemato-Onkologische Praxis und Tagesklinik", 
            "last_name": "Axel R. Hanauske, MD, PhD, MBA", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2000", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004151"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "European Organisation for Research and Treatment of Cancer - EORTC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "European Organisation for Research and Treatment of Cancer - EORTC", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 1999", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }, 
    "geocoordinates": {
        "CHU de la Timone": "43.296 5.37", 
        "Centre de Lute Contre le Cancer,Georges-Francois Leclerc": "47.322 5.041", 
        "Haemato-Onkologische Praxis und Tagesklinik": "48.145 11.558", 
        "Hospital Universitario 12 de Octubre": "40.417 -3.7", 
        "Istituti Fisioterapici Ospitalieri - Roma": "41.891 12.494", 
        "Istituto Nazionale per lo Studio e la Cura dei Tumori": "40.84 14.253", 
        "Kaiser Franz Josef Hospital": "48.208 16.374", 
        "Rigshospitalet": "55.676 12.568"
    }
}